Merck and Otsuka recognized for driving greater equality for women in the workplace.
With gender inequality a continued area of focus for corporations and workplaces around the globe, the Healthcare Businesswomen’s Association (HBA) is proud to recognize Merck & Co., Inc. and Otsuka America Pharmaceutical, Inc. for exemplary workplace initiatives working to close the gender gap in the healthcare and life science industries. The awards will be presented on Wednesday, 10 November, in conjunction with HBA’s virtual Annual Conference.
HBA’s Advancement. Commitment. Engagement. (ACE) Awards recognize companies committed to ensuring that gender diversity and leadership opportunities for women are part of their organizational DNA. An independent panel of healthcare industry leaders selects ACE Award recipients for their excellence in advancing their female talent and removing the systemic barriers preventing timely progress to parity. Award criteria include measurable results, business performance, stewardship, execution, and sustainability.
With a 26-year history, Merck’s Women’s Network validates the organization’s long-term commitment to diversity and inclusion and demonstrates how integral these values are to achieving better healthcare outcomes for the patients they serve. With 10,000 women participating, there are a variety of initiatives supporting the drive to greater equality including a Gender Equality Council, Mentoring Programs, a Women’s Network European Personal Branding Program, and an Executive Speaker Series.
Otsuka’s Network of Otsuka Women (NOW) has delivered impressive influence and impact in a short time since it was founded in 2019. Sponsorship by the company’s CEO and CCO, and support from the board, speak to Otsuka’s commitment to including diversity, equity, and inclusion as key imperatives as part of its global business strategy.
Read more about the winners here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.